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Abstract
Background: Cryptococcal meningitis is the most common fungal infection of the central nervous system (CNS) in
HIV/AIDS. HIV-1 virotoxins (e.g., gp41) are able to induce disorders of the blood-brain barrier (BBB), which mainly
consists of BMEC. Our recent study suggests that α7 nAChR is an essential regulator of inflammation, which
contributes to regulation of NF-κB signaling, neuroinflammation and BBB disorders caused by microbial (e.g., HIV-1
gp120) and non-microbial [e.g., methamphetamine (METH)] factors. However, the underlying mechanisms for
multiple comorbidities are unclear.
Methods: In this report, an aggravating role of α7 nAChR in host defense against CNS disorders caused by these
comorbidities was demonstrated by chemical [inhibitor: methyllycaconitine (MLA)] and genetic (α7−/− mice)
blockages of α7 nAChR.
Results: As shown in our in vivo studies, BBB injury was significantly reduced in α7−/− mice infected with C.
neoformans. Stimulation by the gp41 ectodomain peptide (gp41-I90) and METH was abolished in the α7−/− animals.
C. neoformans and gp41-I90 could activate NF-κB. Gp41-I90- and METH-induced monocyte transmigration and
senescence were significantly inhibited by MLA and CAPE (caffeic acid phenethyl ester, an NF-κB inhibitor).
Conclusions: Collectively, our data suggest that α7 nAChR plays a detrimental role in the host defense against C.
neoformans- and HIV-1 associated comorbidity factors-induced BBB injury and CNS disorders.
Background
Cryptococcal meningitis is the most common fungal
infection of the central nervous system (CNS) and
also the most prevailing neurological complication in
AIDS patients: AIDS patients often develop severe
neuro-degeneration and dementia, which is also habit-
ually aggravated by other ailments such as metham-
phetamine (METH) abuse. Among them, the patients
commonly succumb to the co-infected yeast oppor-
tunistic pathogen Cryptococcus neoformans. The mor-
tality rate of HIV-associated cryptococcal meningitis
is high (~30 %), and is one of the major causes of
death in AIDS patients [1]. In order to cause menin-
goencephalitis, C. neoformans cells must cross the
blood-brain barrier (BBB). The BBB is constituted by
the brain microvascular endothelial cells (BMEC), dis-
tinguished by their tight junctions amongst cells [2].
We have previously studied the invasion of C. neofor-
mans with the human BMEC (HBMEC) using in vitro
binding and transcytosis assays [3, 4]. C. neoformans
induces considerable morphological changes and actin
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reorganization on HBMEC [3]. Some molecular events
have been observed for the formation of the C. neofor-
mans entry site, including: the roles of CD44 [5, 6],
caveolin-1 [7], and PKCα [8] on the membrane lipid rafts,
and the role of endocytic kinase DYRK3 during the C.
neoformans internalization [9]. Perceivably, C. neoformans
implements complicated invasion mechanisms inherent to
this pathogen.
The interrelationship between HIV-1 and C. neoformans
is intriguing, as both pathogens elicit severe neuropatho-
logical complications. We have previously demonstrated
that the HIV-1 gp41 enhances C. neoformans binding to
HBMEC in vitro and increase C. neoformans brain inva-
sion in vivo [10]. We have further elucidated the under-
lying mechanism by showing that both C. neoformans and
gp41-I90 up-regulate ICAM-1 on the HBMEC, cause the
redistribution of CD44 and β-actin on the lipid rafts,
and induce membrane ruffling on the surface of
HBMEC [6, 11]. These results suggest that the HIV-1
gp41-I90 enhances C. neoformans binding with HBMEC
via gp41-I90-induced membrane activities, revealing a po-
tential mechanism for this pathogenic fungus to invade
the brain tissues of HIV-1-infected patients. The progres-
sion of HIV disease and its consequences may be wors-
ened by METH abuse. METH is able has been shown to
increase viral replication in animal models. METH abusers
with HIV have shown greater chance to have neuronal in-
jury and cognitive impairment, compared with the HIV
patients who do not abuse the drug. Many studies have
demonstrated that METH, nicotine and microbial factors
(e.g., gp41 and gp120) were able to significantly cause
functional and structural changes in BBB [3, 12–16]. It
also raised an interesting question: what is the gp41- and
METH-induced host signaling to create such microenvir-
onment that is favorable to the C. neoformans infection.
As such, we can observe the enhanced infection both in
vitro and in vivo [10, 11].
Alpha7 nicotinic acetylcholine receptor (α7 nAChR) is
a major cholinergic ligand-gated ion channel in the
CNS, has been implicated in the modulation of the BBB
integrity and pathogenesis of CNS disorders caused by
microbial (e.g., HIV-1 virotoxins gp120) and non-
microbial (e.g., METH and nicotine) factors [17–19].
Alpha7 nAChR also contributes to the pathogenesis of
Alzeimer’s disease (AD) [20]. It seems that α7 nAChR
could be potential therapeutic target for HIV-1 and re-
lated comorbid factors-induced pathogenicities. Under-
standing the role of α7 nAChR in HIV-1 virotoxins- and
related comorbid factors-induced pathogenicities will
lead to improvements in diagnosis, prevention, and
treatment of NeuroAIDS. Our recent studies have
shown that the α7 nAChR cholinergic pathway is es-
sential for lipid raft (LR)-dependent Ca2+ signal
transduction, which leads to NF-κB activation, CNS
inflammation and leukocyte transmigration across the
BBB [21–23]. In this report, we have hypothesized
that α7 nAChR -mediated signaling is a common
pathway of CNS disorders caused by C. neoformans,
HIV-1 virotoxins (gp41) and METH. We used both
the in vitro (HBMEC) and in vivo (α7 nAChR knock-




Evans blue, methamphetamine (METH) and MLA were
purchased from Sigma-Aldrich (St. Louis, MO). Dyna-
beads M-450 Tosylactivated was purchased from Invi-
trogen (Carlsbad, CA). Ulex europaeus I (UEA I) lectin
and mounting medium with DAPI were purchased from
Vector (Buringame, CA). The Gp41 ectodomain peptide
(gp41-I90) was prepared as described previously [9, 11]. A
senescence β-Galactosidase Staining Kit (Cat#9860) was
bought from Cell Signaling Technology. A Fluoro-Jade B
(FJB) staining kit was obtained from Histo-Chemo Inc. All
primary antibodies (Ab) were purchased from the
commercial sources: a rabbit anti-α7 nAChR Ab from
Genescript (Piscataway, NJ); Anti-NF-κB/p65 mAb
from Cell Signal Technology (Cell Signal Technology,
#3033); an antibody against dimethyl-histone H3
(Lys9) from Millipore (Millipore, cat #.07–212), an
anti-mouse CD146 Ab FITC-conjugated and a mouse
anti-neuron (NeuN) Ab from eBiosciences (San Diego,
CA); a mouse anti-CD44 Ab (sc-7297); a rabbit anti-CD54
Ab (ICAM-1, 250593) from Abbiotec (San Diego, CA); a
rabbit anti-β-actin (sc-7210) and an anti-GFAP Ab from
Santa Cruz Biotechnology (Santa Cruz, CA); an anti-
mouse CD146 Ab FITC-conjugated from Biolegend
(San Diego, CA), and a rabbit anti-S100B Ab from
BD Biosciences.
Strains, media and cultures
B-4500FO2 is a wildtype strain of C. neoformans strain
[4–6]. Yeast cells were grown aerobically at 30 °C in 1 %
yeast extract, 2 % peptone and 2 % dextrose (YPD broth)
or Sabouraud medium (Difco Laboratories, Detroit, MI).
Cells were harvested at an early log phase, washed with
phosphate-buffered saline (PBS) and then resuspended
in Hams-F12 / M199 (1:1, v:v), 5 % heat-inactivated fetal
bovine serum (experimental medium), and 1 % human
serum. The Cryptococcus cell number was determined
by direct counting from a hemocytometer.
Animal model and treatment protocol
Heterozygous (+/−) α7-deficient mice with the C57BL/6 J
background (B6.129S7-Chrna7tm1Bay/J) were purchased
from Jackson Laboratory (Bar Harbor, ME). Genotypes of
α7 +/+ mice (WT mice), α7−/− mice (KO mice) and
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heterozygous α7 +/− mice were determined according to
the PCR protocol provided by the vendor. The animals
were used in transgenic breeding at 8 weeks of age for
optimum reproductive performance. Male heterozygous
(+/−) and female homozygous (−/−) were used in breed-
ing. The average litter size for neonatal mice was 6–8.
Age- and sex-matched mice were used in all experiments.
All experiments were approved by the Animal Care and
Use Committee of Childrens Hospital Los Angeles Saban
Research Institute. Two sets of experiments were per-
formed. In the first experiment, the mice (6 week-old)
were divided into 4 groups (I: WT+METH; II: WT +
PBS; III: KO +METH; IV: KO + PBS). Two groups (I and
III) of animals were treated with gradually increased doses
(2, 4, 6, 8, 10, 10, 10, 10, 10, 10 mg/kg from day1 to
day10) of METH [intraperitoneal (i.p.) injection] for
10 days as described previously [15]. The animals were in-
fected with a total of 106 yeast cells via lateral tail vein in-
jection. After 24 h, the brain was removed, washed with
2 ml PBS. The tissues were homogenized and plate onto
triplicate YPD plates for CFU counting. The presence of
Cryptococcus cells in CSF is an indicator of cryptococcal
meningitis, which was determined as described previously
[4–6]. Briefly, C57LB/6 WT and KO mice were infected
with yeast cells as described above. After 24 h, the animal
was perfused with 20 ml PBS to remove blood circulating
yeast cells. The skull was opened for CSF collection. The
brain was then removed and washed with 500 μl PBS. In
the meantime, the cranial cavity was washed with 100 μl
PBS four times. The washing solutions were combined.
After centrifugation, the pellet was resuspended into
50 μL PBS, designated as the CSF fraction. An aliquot was
used for counting erythrocytes (RBC). Samples were dis-
carded if the CSF was contaminated with blood >25
RBCs/μl present in the sample. The uncontaminated sam-
ples were used for Cryptococcus cell counting. In the sec-
ond experiment, the animals were divided into 4 groups
(I: WT+ gp41-I90 +METH; II: WT + gp41-I90; III: KO+
gp41-I90 +METH; IV: KO+ gp41-I90). Two groups (I and
III) of animals were treated with METH as described in
the first experiment. The animals in Group I-IV received
daily injections from tail veins of endotoxin-free recom-
binant HIV-1 gp41-I90 as described previously [11]. Mice
were infected with yeast cells as described above.
Isolation and purification of mouse brain microvascular
endothelial cells
Mouse CEC and cBMEC were isolated from blood and
brain tissues of the animals in the second experiment
with Ulex europaeus I (UEA I) lectin-coated Dynabeads
as described previously [15]. The beads were prepared
according to the manufacturer’s instructions (Invitrogen)
and resuspended in Hanks' balanced salt solution (HBSS,
Invitrogen Corp., Carlsbad, CA, USA) plus 5 % fetal calf
serum (HBSS + 5 %FCS) to a final concentration of
4 × l08 beads/ml. The CEC and cBMEC were prepared
as described previously [15]. Briefly, endothelial cells
from blood were isolated by absorption to Ulex-coated
beads. The cells were positive for CD146 [15], demon-
strating their endothelial origin, and also expressed S100B
[24], indicating their brain origin. For the cBMEC assays,
the cells were transferred to glass splices to by cytospin
for staining and counting under a fluorescence micro-
scope. Total ECs or CECs (CD146+/DAPI+) and cBMECs
(CD146+/S100B+/DAPI+) were identified based on their
S100B [24] (brain marker)+/CD146 (EC marker)+/DAPI
(nuclei) + phenotypes.
Monocytes transmigration assay
Monocytes suspensions in experimental medium were
used for transmigration assays as described previously
[25]. Briefly, the confluence of the HBMECs monolayers
in transwell filters (3.0 μm pore size, 6.5 mm diameter,
BD Biosciences) coated with collagen was confirmed by
light microscopy before the start of the assay. To test ef-
fects of inhibitors α7 nAChR (MLA), and NF-κB (CAPE)
on gp41- and METH-induced monocyte transmigration
across HBMECs. The HBMECs monolayers were pre-
incubated with different doses of MLA (0, 0.1 μM,
1 μM, 10 μM) for 1 h or CAPE (0, 1 μM, 5 μM, 25 μM)
for 2 h and stimulated with gp41 (10 μg/ml) and
METH(50 nM) in the upper chambers. Then, Freshly
isolated monocyte-like vitamin D3-differentiated HL60
cells (1x106 cells/ml) were added to the upper chamber
and allowed to migrate over for 4 h. The MLA or CAPE
was present throughout the monocytes transmigration
experiment until the end. At the end of the incubation,
migrated HL60 cells were collected from the lower
chamber and counted in a blinded-fashion using a he-
macytometer. Final results of monocytes transmigration
were expressed as the percentage of HL60 cells across
the HBMECs monolayers.
Immunoblotting analysis
To assess C. neoformans- and gp41-innduced NF-κB ac-
tivation in HBMECs, endothelial cell monolayers were
grown on 60-mm plates. Confluent HBMEC monolayers
were incubated with C. neoformans (105/ml), or gp41-
I90 (1 μg/ml) for different time points. After the comple-
tion of incubation, cytoplasmic and nuclear proteins of
HBMECs were extracted with lysis buffer supplied with
100 nM okadaic acid and 1 mM Na3VO4 as described
previously [26]. Both cytoplasmic and nuclear proteins
were mixed with SDS buffer, heated and subjected to so-
dium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS–PAGE). Separated proteins were transferred to
nitrocellulose membrane by semi-dry blotting. After
blocking with 5 % milk in PBS with 0.1 % Tween 20 for
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2 h, cytoplasmic and nuclear proteins were probed
with antibodies against phospho-NF-κB/p65 (ser536)
and β-actin overnight, respectively. The washed mem-
branes were incubated with a horseradish peroxidase
(HRP)-conjugated secondary antibody for 1 h and
then visualized using an enhanced chemiluminescence
procedure (Roche Applied Science, Indianapolis, IN).
Analysis of HBMECs and astrocytes senescence induced
by C. neoformans and gp41-I90
The detection of senescence phenotypes of HBMEC and
astrocytes was according to the kit procedure of Cell
Signaling Technology. Briefly, after the treatment with
1 μg gp41-I90 for 24 h, HBMECs were rinsed with PBS
one time. Cells were fixed with 1 × fixative solution for
10–15 min at room temperature prior to be stained with
β-Galactosidase staining solution at 37 °C for at least
3 days. About 500 randomly selected cells per sample
were photographed under a microscope (200× total
magnification) with positive cells developing blue color.
Senescence associated heterochromatin formation (SAHF)
were detected with the Narita’s method [27]. Cells were
treated same as β-Galactosidase activity detection, then
stained with an antibody against dimethyl-histone H3
(Lys9) and DAPI.
Histology staining of neural tissue
Mice brains were harvested for fluoro-Jade B (FJB) stain-
ing [28, 29] and immunostaining with an anti-NeuN
antibody [30] after infection, fixed in 10 % buffered for-
malin for 24 h, embedded in paraffin, and sections with
5 μm thickness were prepared. Dried mounted brain sec-
tions were fixed with 4 % PFA vapors in a closed con-
tainer placed in a water bath heated at 37 °C for 2.5 h.
Slides were dehydrated and rehydrated through graded
concentrations of alcohol (50, 70, 100, 70, and 50 % al-
cohol, 1 min each), and rinsed with distilled water for
1 min. Slides were then treated with potassium perman-
ganate (0.06 %) for 10 min and rinsed for 1 min in dis-
tilled water, prior to be stained in 0.004 % FJB in 0.1 %
acetic acid for 20 min. Finally, Slides were rinsed in dis-
tilled water (3 × 1 min), dried overnight at 37 °C, then
imaged with flour-microscopy. To perform immuno-
staining, the tissue sections were stained with a FITC-
conjugated mouse antibody against neuron-specific nu-
clear protein (NeuN) (eBiosciences), and counterstained
with DAPI. Image fluorescence quantification analysis
was performed with program MetaMorph (Version
7.7.3.0) and TUNEL assays. For each treatment, 5–6
mouse brains were sectioned and stained.
Statistical analysis
The statistical analysis of the data from our study in-
volved analysis of variance (ANOVA). The dependent
variable was the associated percent of cells or CFU while
the independent fixed factors were be the treatments
(wildtype vs. KO). Raw data was entered into EXCEL
files and automatically converted to the compatible for-
mat for statistical analysis packages. ANOVA and co-
variates were followed by a multiple comparison test
such as the Newmann-Keuls test to determine the statis-
tical significance between the control and treatment
groups. P < 0.05 was considered to be significant.
Ethics statement
All research involving human participants has been
approved by the Institutional Review Board (IRB) of
Children’s Hospital Los Angeles (CHLA). Human brain
microvascular endothelial cells (HBMEC) were isolated in
accordance with the protocol approved by the CHLA
Committee on Clinical Investigations (CCI), which is the
IRB for Human Subjects at Saban Research Institute of
CHLA. This protocol has been granted a waiver of in-
formed or signed consent per 45 CFR 46.116(d) and a wai-
ver of HIPAA authorization per the Privacy Rule (45 CFR
Part 160 and Subparts A and E of Part 164). No mi-
nors/children participants were involved in our stud-
ies. The animal study was performed in strict accordance
with the recommendations in the Guide for the Care
and Use of Laboratory Animals of the National Insti-
tutes of Health. Our protocols were approved by the
Institutional Animal Care and Use Committee (IACUC)
of The Saban Research Institute of CHLA (Permit num-
ber: A3276-01). All surgery was performed under
anesthesia with ketamine and lidocaine, and all efforts
were made to minimize suffering.
Results
Alpha7 nAChR- and NF-κB-mediated signaling is required
for monocyte transmigration across HBMEC
Monocyte recruitment into the CNS plays a crucial role
in the inflammatory response induced by HIV-1 and re-
lated comorbidity factors [31–33]. In order to exclude
the possibility that the leukocyte migration elicited was
due to destruction of HBMEC, the integrity of the
monolayer was inspected by microscopy. HBMEC were
exposed to METH (50 nM) and gp41-I90 (10 μg/ml) for
48 h, different doses of MLA (1–10 μM) for 1 h or
CAPE (1–25 μM) for 2 h, and subjected to monocyte
transmigration assays. As indicated in Fig. 1a-d, gp41-
I90 and METH could significantly increase leukocyte
transmigration. The inhibitors of NF-κB (CAPE) and α7
nAChR (MLA) were able to significantly inhibit mono-
cyte transmigration across the HBMEC monolayer
treated with gp41-I90 (Fig. 1a and c) and METH (Fig. 1b
and d) in a dose-dependent manner. These results sug-
gest that α7 nAChR- and NF-κB-mediated signaling is
required for leukocyte transmigration across the blood-
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brain barrier. It is consistent with the prior reports that
α7 nAChR is able to regulate the NF-κB signaling path-
way [15, 34].
Alpha7 knockout mice are defensive in C. neoformans-,
METH- and gp41-I90- induced BBB injury
To further validate the biological relevance of the in vitro
assays, the role of α7 nAChR in the pathogenesis of CNS
disorders induced by HIV-1 and related comorbidity fac-
tors was tested in the mouse model, as described in
Methods and Materials. The host susceptibility to BBB in-
jury induced by these pathogenic insults was tested in α7
nAChR wildtype (α7+/+) and KO (α7−/−) mice pretreated
with METH or gp41-I90. Animals of the same age were
injected through tail vein with C. neoformans (2x106
CFU), followed by Evans blue (EB) injection after 15 h. As
shown in Fig. 2a, EB was significantly decreased in the
brain tissues of KO mice as compared to that of wildtype
animals (P < 0.01), suggesting that α7 nAChR plays an im-
portant regulatory role in the BBB integrity. This re-
sult showed that the magnitude of EB was significantly
increased by METH exposure only in wildtype mice
(P < 0.001), but not in KO mice, suggesting that α7
nAChR is essential for METH-enhanced C. neofor-
mans-induced pathogenicities (Fig. 2a-b). However,
there is no significant age difference between the two
groups (45 days in Fig. 2a vs 75 days in Fig. 2b) of
animals. Similarly, as shown in the Fig. 3b, the cell-
based BBB biomarker cBMEC in the blood was sig-
nificantly reduced in KO mice as compared to wild-
type animals (P < 0.01). The blood levels of CEC,
which is the cell-based biomarker of peripheral vascula-
ture, were remarkably decreased in KO mice (Fig. 3a), sug-
gesting that α7 nAChR also contributes to the regulation
Fig. 1 Effects of blockages of α7 nAChR and NF-κB on gp41-I90- and METH-induced monocyte transmigration across BBB. HBMECs were
pre-incubated with or without gp41-I90 (10 μg/ml) and METH (50 nM) for 48 h, and then treated with different doses of inhibitors CAPE
(0, 1 μM, 5 μM, 25 μM) for 2 h or MLA (0, 0.1 μM, 1 μM, 10 μM) for 1 h before the Monocytes transmigration assays. Freshly isolated
monocyte-like vitamin D3-differentiated HL60 cells (1x106 cells) were added to the upper chamber and allowed to migrate over for 4 h.
(a-b) CAPE (NF-κB inhibitor) could dose-dependently block gp41- and METH-induced monocyte transmigration across HBMEC. (c-d) MLA
(α7 antagonist) was able to inhibit gp41- and METH-induced monocyte transmigration across HBMEC in a dose-dependent manner. Values
represent the means of relative transmigrating monocytes of triplicate samples. In (a-d), the experimental setting without inhibitor treatment
was taken as a control (the first column). Bar graphs showed the means ± SD of the triplicate samples. *P < 0.05, **P < 0.01
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of the peripheral vasculature integrity. Taken together,
these data suggested that α7 nAChR could play a detri-
mental role in the host defense against C. neoformans,
HIV-1 gp41 and METH.
C. neoformans- and gp41-I90- induced cytoplasmic
activation and nuclear translocation of NF-κB
As shown in our previous studies [11], gp41-I90 is able
to significantly enhance C. neoformans meningitis. Be-
cause the mechanisms by which C. neoformans and gp41
induce signaling are still poorly understood and the initi-
ation of NF-κB activation and subsequent nuclear trans-
location is not clear, we performed time course analysis
of C. neoformans- and gp41-I90-induced NF-κB activa-
tion and translocation. HBMECs were treated with C.
neoformans- and gp41-I90. The proteins from cytoplas-
mic and nuclear fractions were examined in Western
blots using the antibody against the activated NF-κB/p65
(ser536). As shown in Fig. 4a, C. neoformans (the upper
panel) and gp41-I90 (the lower panel) could increase
cytoplasmic NF-κB activation and subsequent nuclear
translocation in a time-dependent manner. NF-κB acti-
vation resulted in up-regulation of inflammatory factors
CD44 and ICAM-1 (Fig. 4b). These findings suggest that
NF-κB signaling is required for CNS disorders caused by
C. neoformans and HIV-1 virulence factors.
C. neoformans- and gp41-I90- induced Neuronal injury in
the brain sections containing prefrontal cortex
Both HIV-1 and C. neoformans cause severe neuronal
damages, and the age population is more vulnerable to
these ailments [35]. The onset, process and interrelation-
ship with pathogen insults relevant to the age are still
not clear. We have used the neuronal markers, fluoro-
Jade B (FJB) [28, 29] and NeuN [30], to examine the in-
fected mouse brains. The enhancement of FJB signals in-
dicates the increase of neuronal degeneration (Fig. 5a).
On the other hand, the disappearance of the NeuN sig-
nals around the cystic lesion suggests the loss of neuron
cells in the damaged area (Fig. 5b).
Fig. 2 Effects of genetic blockage of α7 nAChR on C. neoformans (Cn)- and METH-increased BBB permeability. Mice were infected with Cn at
45 days (a) and 75 days (b). Evaluation of BBB permeability to Evans blue in Cn-infected WT and KO mice with or without METH exposure
(n = 6–8). **P < 0.01, ***P < 0.001
Fig. 3 Effects of A7R KO on BBB disorders induced by gp41-I90 and METH. cBMECs were isolated from WT and A7R KO mice treated with
gp41-I90 (GP41) or METH as described in our recent publications [9, 49]. Cells without treatment were used as a control. Triple staining
(TS) was done by DAPI (blue)/antibodies against CD146 (FITC/green) and S100B (for brain) (rhodamine/red). a: CECs (CD146+/DAPI+), and
b: cBMECs (CD146+/S100B+/DAPI+). Cells were counted with six random fields. (*P <0.05; **P < 0.01; ***P < 0.001)
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HIV-1 gp41-I90- and comorbidity factors-induced senescence
in HBMECs and astrocytes were blocked by the α7 nAChR
antagonist MLA
As the age population increases and HIV-1 infection in-
creases in older population, the incidence of NeuroAIDS
becomes higher and accelerated among the aging popula-
tions. Likewise, in C. neoformans infection, age ≥60 year-
old is a significant predictor of the mortality [36, 37]. To
test whether gp41 and comorbidity factors were able to in-
duce senescence in HBMECs, which could be blocked by
the α7 antagonist MLA, HBMECs were treated with C.
neoformans and gp41-I90. Senescence associated hetero-
chromatin formation (SAHF) were detected with the
Narita’s method. β-Galactosidase activity was measured.
The cells were stained with DAPI and an antibody against
dimethyl-histone H3 (Lys9). These morphological changes
and the increase in SA β-gal stained cells confirmed that
HIV-1 gp41-I90 and C. neoformans efficiently induced the
premature senescence of HBMECs (Fig. 6a). Next, the α7
antagonist MLA was used to illustrate the roles of α7
nAChR in gp41-I90 and its comorbid factor-induced pre-
mature senescence of HBMECs and astrocytes. We com-
pared senescence of HBMECs and astrocytes upon
exposure to gp41-I90, METH, METH+ gp41-I90, and
treatment with MLA 1 h before incubation with these
stimulating agents. When treated with either 1 μg/ml
gp41-I90, 50 nM METH or METH (50 nm) + gp41-I90
(1 μg/ml) (24 h), HBMECs and astrocytes became flat and
showed enlarged morphology, which is a characteristic
phenotypic change in premature senescence. MLA
significantly reduced these morphological changes and
the number of SA β-gal stained HBMEC (Fig. 6b) and
Fig. 4 C. neoformans (Cn)- and gp41-I90- induced activation of
NF-κB/p65 that resulted in up-regulation of CD44 and ICAM-1. (a)
HBMEC were treated with either Cn cells (upper, 105 cells/mL) or
gp41-I90 (bottom, 1 μg/mL), and harvested at different time points
as indicated. Cell pellets were fractionated into cytosol and nuclear
fractions, and subjected to the Western blots. Cyto (30 μg) and Nuc
(10 μg) per lane were loaded. An anti-NF-κB/p65 mAb was used to
probe the phosphorylation site Ser(536) of NF-κB/p65. (b) Expression
of CD44 and ICAM-1 were examined (Cn 107 cells/mL or gp41-I90
20 μg/mL, 6 h), respectively, using antibodies against CD44 and
ICAM-1. β-Actin was the loading control
Fig. 5 Neuronal damages of Cn infected brains that contain prefrontal cortex. (a) The FJB signals of the control (a) and Cn-infected mouse
brain sections (5 day infection) (b) are shown. The yellow box is magnified shown in below. Mean number of FJB positive neurons/mm2 (n = 5)
at 5- and 16- days are significantly different from the mock control (*P < 0.05). (b) A Cn-infected brain section shows (a) nuclear DNA (DAPI
stain), (b) neuron cells (NeuN), (c) reactive astrocytes (GFAP), and (d) the overlaid image. The upper part of the image seems normal, but the
lower part shows that the reactive astrocytes surrounding the cystic lesions (yellow arrows), where the NeuN signals disappear near the lesions.
Similar observations were obtained from gp41-I90 treatment, but the signals were more dispersed through the whole brain section (data
not shown)
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astrocytes (Fig. 6c). These results suggest that α7 an-
tagonist MLA suppresses HIV-1 gp41-I90 and comor-
bidity factors-induced senescence in HBMECs and
astrocytes.
Discussion
Currently, the mechanisms responsible for the pathogen-
esis of the CNS disorders caused by HIV-1 and related
comorbidity factors remain unclear. An important con-
nection between the nervous system and the inflamma-
tory response to disease has been uncovered through
identification of α7 nAChR, an ion channel highly perme-
able to calcium, as an essential regulator of inflammation
[38–40]. Alterations of brain microvascular endothelial
cells (BMEC), which form the BBB, and the pathogenesis
of neurodegenerative disorders (ND), are commonly asso-
ciated with HIV-1 infection, the use of drugs and the aging
processes in the era of HAART. A few reports suggested
that neuronal α7 nAChR could be activated by HIV-1
virulence factors (e.g., gp120) and related comorbidity fac-
tors (e.g., METH) [17, 41–43]. Recent studies show that
stimulation of nAChRs impairs the host defense against
various microbial infections [15, 44, 45]. The underlying
mechanisms of these multiple comorbidities, however, are
largely unknown. We have proposed that the HIV-1-re-
lated multiple CNS comorbidities are driven by a
common set of genes and pathways regulated by α7
nAChR through conveying signaling information from
the channel Ca2+ current to IKK/NF-κB activation
cascade, leading to upregulation of the proinflamma-
tory factors and enhancement of HIV virotoxins- and
comorbidity factors-mediated pathogenicities [15]. It
has been suggested that a7 nAChR-mediated NF-kB
signaling may be involved in regulation of both the
molecular (UCHL1 and S100B) and cellular (cBMEC
shedding) biomarkers during various CNS disorders
[15]. Using gene knockout mice, we have demonstrated
that α7 nAChR plays a detrimental role in the host
defense against CNS inflammation caused by micro-
bial (e.g., meningitic pathogens and gp120) and non-
microbial factors (e.g., nicotine and METH) [15, 45].
Regulation of intracellular calcium by α7 nAChR can
lead to activation of signal transduction pathways, in-
cluding ERK1/2 and calmodulin-dependent kinase II
[44, 45]. In the current study, we demonstrated that
CNS disorders induced by C. neoformans and HIV-1
associated comorbidity factors could be significantly
inhibited by chemical and genetic blockages of α7
nAChR. These new findings concur with our previous
studies that gp41 is one of the primary neurotoxins re-
sponsible for NeuroAIDS, which significantly enhance
meningitic pathogenicities of C. neoformans [10, 11]. Fur-
thermore, these pathogenicities are enhanced by METH,
one of the commonly abused drugs in patients infected
with HIV-1, in a manner dependent on α7 nAChR.
The NF-κB pathway is being increasingly recognized
as a good signaling paradigm for molecular biomedicine
[46]. This pathway, which is the master regulator of the
innate immunity, plays important roles in maintaining
cell homeostasis/ differentiation, and regulating the host
response to microbial infections [26]. There are five dif-
ferent members in the NF-κB protein family, including
p65/RelA, c-Rel, RelB, NF-κB2/p52, and NF-κB1/p50,
and sharing a Rel homology domain that mediates DNA
binding and dimerization [26]. In resting cells, NF-κB is
trapped in the cytoplasm by inhibitory IκB proteins.
The NF-κB activation process is induced by phosphor-
ylation of serine residues on the IκB proteins, which are
then subjected to ubiquitination and proteasomal degrad-
ation. Deregulated activity of this pathway has been linked
Fig. 6 Senescence phenotypes of HBMECs and astrocytes are induced by HIV-1 related comorbidity factors and blocked by MLA. (a) SA-βgal images
of HBMEC were obtained with the treatment of: (a) mock, (b) 1 μg gp41-I90 for 24 h, (c) Cn cells (104 cells) in a chamber slide for 24 h. Blue spots in (b)
& (c) indicate senescence cells. For SAHF images, HBMEC was treated with 1 μg gp41-I90 for 24 h, and stained with an antibody against dimethyl-
histone H3 (Lys9). Immunofluorescence microscopic images detect (e) nuclear DNA (DAPI, blue), (f) heterochromatin foci =(SAHF, red), and (g) the
overlaid image. Bar = 25 μm. (b) a: Control (HBMECs), b: gp41-I90 (1 μg/ml), c: METH (50 nM), d: gp41-I90 (1 μg/ml) + METH (50 nM), e: MLA+ gp41-I90
(1 μg/ml), f: MLA+ METH (50 nM). (c) a: Control (astrocytes), b: gp41-I90 (1 μg/ml), c: METH (50 nM), d: gp41-I90 (1 μg/ml) +METH (50 nM),
e: MLA+ gp41-I90 (1 μg/ml), f: MLA+ METH (50 nM)
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to the progression of a number of human diseases, includ-
ing cancers, HIV-1 infection and substance abuse disor-
ders [46–51]. NF-κB activation has been shown to
contribute to comorbidity between gp120 and cocaine in
neurons [50] or METH in astrocytes [51]. NF-κB inhibi-
tors have been found to reduce the CNS inflammation
[52]. Our study demonstrated that C. neoformans and
gp41-I90 could induce cytoplasmic activation and nuclear
translocation of NF-κB in HBMEC through phosphoryl-
ation of the p65 subunit at serine 536. gp41-I90- and
METH-induced inflammatory response is significantly
blocked by inhibitors of α7 nAChR (MLA) and NF-κB
(CAPE). These findings suggest that α7 nAChR is required
for the modulation of NF-κB activation, which may play
an important role in the pathogenesis of CNS comorbidi-
ties caused by HIV-1 virotoxins (e.g., gp41) and related
factors (e.g., C. neoformans and METH). The mechanisms
underlying these comorbidities remain to be elusive.
It is likely that a common set of genes and pathways
regulated by the common receptor α7 nAChR for
these comorbidity factors through conveying signaling
information from the channel Ca2+ current to IKK/
NF-κB activation cascade, leading to the balanced
regulation of the proinflammatory and anti-inflammatory
factors since the NF-κB signal transduction pathway is the
master regulator of the innate immunity.
As the age population increases and HIV-1 infection
increases in older population, the incidence of Neu-
roAIDS becomes higher and accelerated among the
aging populations. Likewise, in C. neoformans infection,
age ≥60 year-old is a significant predictor of the mortal-
ity [36, 37]. The incidence of HIV-1 associated neuro-
cognitive disorders (HAND) also increases with age.
Current projections suggest that more than 50 % of HIV
+ patients in the United States will be over 50 years old
by 2015 [53]. With advancing age, HIV + patients may
potentially develop other neurodegenerative disorders,
including Alzheimer's disease. Thus, aging becomes an
increasing health concern for these diseases currently.
Aging is a complex process, derived from a variety of
different mechanisms. Recent studies have suggested
that one of the potential mechanisms is the activation of
the NF-κB signaling, resulting in chronic inflammatory
responses known as the senescence-associated secretory
phenotype (SASP) [54–56]. Further, hyper-activation of
NF-κB by HTLV-1 Tax can induce cellular senescence
[57]. It has been proven that both genetic and pharma-
cological inhibition of NF-κB signaling prevents age as-
sociated features in the animal models, significantly
extending their longevity [58]. To test whether and how
the α7 nAChR-regulated NF-κB signaling is linked to the
pathogenesis and senescence of HIV-1 gp41-I90, METH
and C. neoformans invasion, we have used the neuronal
markers, fluoro-Jade B (FJB) [28, 29] and NeuN [30], to
examine the infected mouse brains. The enhancement of
FJB signals indicates the increase of neuronal degener-
ation. On the other hand, the disappearance of the
NeuN signals around the cystic lesion suggests the loss
of neuron cells in the damaged area. Results from this
experiment have provided preliminary support for the
hypothesis that the aged mice are more susceptible to
pathogen insults, and the vulnerability can be reflected
from more brain neuronal damages and the loss of the
BBB integrity. BBB dysfunction has been implicated as a
crucial event in the development of several aging-related
CNS disorders, including Alzheimer disease, Parkinson
disease, multiple sclerosis, and HAND [59]. Furthermore,
gp41-I90- and METH-induced senescence in HBMECs
and astrocytes could be very efficiently blocked by the α7
antagonist MLA, suggesting that α7 nAChR is essential
for this pathogenic process.
Conclusions
Taken together, the major finding of the present report
is that both chemical and genetic blockages of α7
nAChR are protective against C. neoformans- and HIV-1
associated comorbidity factors-induced BBB injury and
CNS disorders by down-regulation of cBMEC shedding,
monocyte recuitment, NF-κB signaling, senescence and
neuronal inflammation. Further insight into how C. neo-
formans and HIV-1 associated comorbidity factors utilize
the host cholinergic α7 nAChR pathway to augment
their virulence capacity will advance our understanding
of the pathogenesis and therapeutics of CNS disorders
caused by multiple comorbidities.
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